𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis

✍ Scribed by Jérémie Sellam; Stéphanie Rouanet; Houria Hendel-Chavez; Karim Abbed; Jean Sibilia; Jacques Tebib; Xavier Le Loët; Bernard Combe; Maxime Dougados; Xavier Mariette; Yassine Taoufik

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
235 KB
Volume
63
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reconstitution of peripheral blood B cel
Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis
✍ Maria J. Leandro; Geraldine Cambridge; Michael R. Ehrenstein; Jonathan C. W. Edw 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 1 views

## Abstract ## Objective To study the quantitative and phenotypic reconstitution of peripheral blood B cells and its relationship to the dynamics of clinical response in patients with rheumatoid arthritis (RA) following B cell depletion with rituximab. ## Methods Twenty‐four patients with active

Ability of the American College of Rheum
Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later
✍ Alain Saraux; Jean M. Berthelot; Gérard Chalès; Catherine Le Henaff; Jean B. Tho 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 2 views

Objective. To determine how well the American College of Rheumatology (ACR; formerly, the American Rheumatism Association) 1987 classification criteria for rheumatoid arthritis (RA), when used at study inclusion in a cohort of 270 patients with early (<1 year) arthritis, predicted a diagnosis of RA

B cell depletion may be more effective t
B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents
✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt